Patent · US Active

Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes

US11267924B2 · kind B2 · utility

0Cited by

53References

7Claims

0Family size

Assignee

Genzyme Corporation · US

Inventors

Pradeep K. Dhal · Westford, US
Robert J. Miller · Halifax, US
Steven C. POLOMOSCANIK · Belmont, US
Philip Just Larsen · Vejle, DK
Thomas Huebschle · Frankfurt am Main, DE
Thorsten Schmidt · Horgen, CH
Ian Davison · Kedington, GB
Peter D. McDonnell · Cwmbran, GB
Chinyere Agbugba · Haverhill, GB

Key dates

Filing date	Dec 16, 2015
Grant date	Mar 8, 2022
Priority date	—
Expiry date	Apr 23, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC08F26/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.